A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)
Latest Information Update: 01 Aug 2025
At a glance
- Drugs Cabotegravir (Primary) ; Rilpivirine (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms CROWN
- Sponsors ViiV Healthcare
Most Recent Events
- 17 Jul 2025 Planned End Date changed from 8 Dec 2027 to 17 May 2028.
- 17 Jul 2025 Planned primary completion date changed from 13 May 2026 to 26 Oct 2026.
- 19 Feb 2025 Planned number of patients changed from 324 to 332.